CRISPR Therapeutics AG
CRSP
$56.25
-$0.43-0.76%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -0.34% | 3.12% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -0.34% | 3.12% | |||
| Cost of Revenue | -43.77% | -11.50% | |||
| Gross Profit | 44.11% | 11.60% | |||
| SG&A Expenses | -10.49% | -1.97% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.76% | -10.27% | |||
| Operating Income | 0.76% | 10.34% | |||
| Income Before Tax | 48.94% | -53.65% | |||
| Income Tax Expenses | -52.09% | 16.50% | |||
| Earnings from Continuing Operations | 48.96% | -53.35% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 48.96% | -53.35% | |||
| EBIT | 0.76% | 10.34% | |||
| EBITDA | 0.62% | 10.62% | |||
| EPS Basic | 51.33% | -51.36% | |||
| Normalized Basic EPS | 9.09% | 18.78% | |||
| EPS Diluted | 51.25% | -51.66% | |||
| Normalized Diluted EPS | 9.09% | 18.78% | |||
| Average Basic Shares Outstanding | 4.86% | 1.32% | |||
| Average Diluted Shares Outstanding | 4.86% | 1.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||